• Company
• From obesity to brain diseases...expansion of GLP-1 agonists
• by Son, Hyung-Min Jul 11, 2024 05:46am

• Policy
• Debate within the Health and Welfare Committee members
• by Lee, Jeong-Hwan Jul 10, 2024 05:48am

• InterView
• ‘Ireland, a bridgehead for companies entering the EU mkt'
• by Nho, Byung Chul Jul 10, 2024 05:48am

• Company
• GC Biopharma ships first batch of ‘Alyglo’ to the U.S.
• by Son, Hyung-Min Jul 10, 2024 05:48am

• Policy
• Reimbursement application submitted for 'Adempas tab'
• by Lee, Tak-Sun Jul 10, 2024 05:48am

• Company
• Tecentriq reapplies for reimb in early stage NSCLC
• by Eo, Yun-Ho Jul 10, 2024 05:48am

• Company
• With Lixiana and Enhertu, Daiichi-Sankyo’s sales growth↑
• by Hwang, Byung-woo Jul 9, 2024 06:07am

• Company
• Industry struggles to develop new atopic dermatitis drugs
• by Son, Hyung-Min Jul 9, 2024 05:51am

• Policy
• 1st bispecific antibody Epkinly approved with a condition
• by Lee, Hye-Kyung Jul 9, 2024 05:51am

• Company
• Takeda seeks top-line growth to KRW 300 billion
• by Hwang, Byung-woo Jul 9, 2024 05:51am